Chugai, Galderma Form Pact for Skincare Drug
By

Chugai Pharmaceutical, the Tokyo-based subsidiary majority-owned (60%) by Roche, and Galderma Pharma, a Lausanne, Switzerland-based pharmaceutical company specializing in skincare pharmaceuticals, have formed a license agreement for nemolizumab, Chugai's anti-interleuken-31 receptor-A humanized monoclonal antibody, which is currently under development for atopic dermatitis and pruritus.

Chugai will grant Galderma an exclusive license for the development and marketing of nemolizumab worldwide, with the exception of Japan and Taiwan. Chugai will continue to be responsible for product manufacturing and supply of the product and will receive upfront, milestone and royalty payments from Galderma.

Chugai has obtained positive results in a global Phase ll clinical study for moderate-to-severe atopic dermatitis in five countries in the United States, Europe and Japan. A Phase ll study for pruritus is currently ongoing in Japan. Nemolizumab was discovered by Chugai and uses Chugai's proprietary antibody engineering technology ACT-Ig, which can extend the biological half-life of antibodies in the blood.

This licensing agreement is subject to potential competition authority clearances and other customary closing conditions.

Source: Chugai

Leave a Reply

Your email address will not be published.